The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Analysis of the EORTC/FIL/LYSA H10 and RAPID trials
Igor Aurer, MD, PhD, University of Zagreb, Zagreb, Croatia, discusses recent analysis of the Phase III EORTC/FIL/LYSA H10 (NCT00433433) and UK NCRI RAPID trials (NCT00943423). Both studies concluded that patients with Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) but no radiotherapy had an increased risk of relapse but an unaffected overall survival (OS). The H10 trial additionally concluded that sex and stage of the disease affected prognosis, but this was not reproducible with data from the RAPID trial. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
